论文部分内容阅读
目的探讨CTF方案新辅助化疗后乳腺癌组织survivin和Ki-67的表达及其临床意义。方法应用免疫组化SABC法检测60例行新辅助化疗和60例未行新辅助化疗的乳腺癌组织中survivin和Ki-67的表达水平。结果新辅助化疗组survivin和Ki-67阳性率分别为36.7%和38.3%,明显低于对照组的71.7%和61.7%(均P<0.05);新辅助化疗组survivin的表达与Ki-67表达呈正相关(r=0.47,P<0.05)。新辅助化疗组总有效率73.3%;化疗后部分缓解者survivin阳性率为18.2%,明显低于无效者的81.3%(P<0.01);化疗后部分缓解者Ki-67阳性率为47.7%,低于无效者的56.3%(P>0.05)。结论应用CTF方案新辅助化疗缓解率高,近期疗效明显。CTF化疗药物,可能通过抑制乳腺癌survivin表达而抑制肿瘤的增殖。
Objective To investigate the expression of survivin and Ki-67 in breast cancer after neoadjuvant chemotherapy with CTF regimen and its clinical significance. Methods Immunohistochemical SABC method was used to detect the expression of survivin and Ki-67 in 60 cases of neoadjuvant chemotherapy and 60 cases of breast cancer without neoadjuvant chemotherapy. Results The positive rates of survivin and Ki-67 in the neoadjuvant chemotherapy group were 36.7% and 38.3%, respectively, which were significantly lower than those in the control group (71.7% vs 61.7%, all P <0.05) (R = 0.47, P <0.05). The total effective rate of neoadjuvant chemotherapy group was 73.3%. The positive rate of survivin in partial remission after chemotherapy was 18.2%, significantly lower than that of ineffective 81.3% (P <0.01); The positive rate of Ki-67 in partial remission after chemotherapy was 47.7% 56.3% less than invalid (P> 0.05). Conclusion CTF regimen neoadjuvant chemotherapy response rate is high, the recent curative effect is obvious. CTF chemotherapy drugs, may inhibit tumor proliferation by inhibiting the expression of survivin in breast cancer.